TSMC faces overvaluation, high CapEx, flat AI demand, and margin pressure, limiting future returns and upside potential.
Cecilia Bahit, MD, and Carolyn Lam, MBBS, PhD, FACC, discuss the barriers patients face when seeking access to clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback